Bristol-Myers Squibb stock price forecast: consolidation likely as BMY eyes upper range resistance

Traders Union
All News
Companies
Bristol-Myers Squibb up 0.83% today

All news

Editors' Picks

Crypto News

Financial News

Market Voices

Billionaires

Companies

Broker News

Regulators News

Hanna Syniavska

27.03.2026

Bristol-Myers Squibb stock price forecast: consolidation likely as BMY eyes upper range resistance — Bristol-Myers Squibb up 0.83% today

Bristol-Myers Squibb presented new clinical and real-world data in symptomatic obstructive hypertrophic cardiomyopathy at ACC26.

The company stated these data build on its research. Results show outcomes across diverse patient populations.

Highlights

Bristol-Myers Squibb is exhibiting sustained medium- and long-term bullish momentum, supported by trading above key moving averages.
Short-term technical signals are mixed, with overbought oscillators suggesting possible near-term pullback amid prevailing buyer dominance.
Expected weekly trading range is $58.20 to $60.80, with high probability of consolidation at the upper end and limited downside risk.

Bristol-Myers Squibb (BMY) is trading at $59.43, below the SMA-20 ($59.76) but above both the SMA-50 ($58.72) and the SMA-200 ($50.57), which signals continued medium- and long-term bullish momentum despite slight short-term resistance. The Ichimoku Kijun level on D1 is $59.67, which stands just above the current price and acts as immediate resistance; near-term support is at the SMA-50 ($58.72), and key support is at the SMA-200 ($50.57), while immediate resistance is at the Kijun ($59.67) and key resistance at the SMA-20 ($59.76).

Momentum signals on D1 are mixed: ADX shows a modest uptrend, but the MACD suggests mild short-term selling pressure. RSI is neutral-bullish at 51.7, while Stoch RSI and BBP both flag overbought conditions, indicating increased buyer dominance and a potential for near-term pullback. CCI and the AO both read neutral, highlighting diverging signals across oscillators. Over the past week, BMY has risen $1.95 (3.39%) from a previous close of $57.48, now standing at the very top of the weekly range after a steady advance. Weekly volatility stands at 5.4%, and the tone shows strength, with price stretching toward weekly resistance levels.

Looking ahead, the expected trading range for the next week is $58.20 to $60.80, placing the forecast near the upper third of the 52-week range and well above the annual low of $42.52 but below the high of $62.89. Given all weekly indicators—RSI, ADX, MACD, and MA-50—are bullish, the probability of a price increase is very high (more than 80%), while a decrease is less likely. The baseline scenario is for BMY to consolidate in a sideways band around current levels. A bullish move would see a sustained break above $59.76–$59.67, potentially targeting the high end of the forecast range. A bearish reversal would require a break below $58.72, exposing support near $58.20, but prevailing momentum and higher timeframe indicators suggest downside is limited for now.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Bristol Myers Squibb received regulatory approval for its immunotherapy combinations targeting classical Hodgkin lymphoma. Investors should now focus on any upcoming developments in the oncology segment, as breakthrough therapies remain a crucial driver for the company’s long-term growth narrative.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.